Edgar Filing: Menzaghi Frederique Ph.D. - Form 4

Menzaghi Frederique Ph.D. Form 4 January 26, 2018 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

See Instruction

Check this box

if no longer

subject to

Section 16.

Form 4 or

obligations

Form 5

1(b).

1. Name and Address of Reporting Person <u>*</u> Menzaghi Frederique Ph.D.			2. Issuer Symbol	Name and	Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer			
			Cara Th	erapeutic	s, Inc. [CARA]	(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction					,	
			(Month/D	ay/Year)		Director	10%		
C/O CARA		01/24/20)18		XOfficer (give titleOther (specify below)				
	ELM STREET, 9	TH				Sr VP-Research & Development			
FLOOR								-	
		4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check				
			Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by One Reporting Person			
STAMFORD, CT 06902						Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table	e I - Non-D	erivative Securities Acc	quired, Disposed	of, or Beneficial	lly Owned	
1.Title of	2. Transaction Da	te 2A. Deer	med	3.	4. Securities Acquired	5. Amount of	6. Ownership	7. Nature of	
Security	(Month/Day/Yea	^	n Date, if		on(A) or Disposed of	Securities	Form: Direct	Indirect	
(Instr. 3)		any		Code	(D) (L + 2 + 15)	Beneficially	(D) or	Beneficial	
		(Month/I	Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)	Owned Following	Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
						Reported	(11301. 4)	(1150. 7)	

		Code	V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	01/24/2018	S <u>(1)</u>		15,000	D	\$ 15	122,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Derivative C Security o (Instr. 3) P	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D)			7. Title and Amount of Underlying Securities (Instr. 3 and	Derivative Security (Instr. 5)	
Dener		Code V	(Instr. 3, 4, and 5) (A) (D)	Date Exercisable	Expiration Date	Amo or Title Num of Share	ber	

Edgar Filing: Menzaghi Frederique Ph.D. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 107 ELM STREET, 9TH FLOOR STAMFORD, CT 06902			Sr VP-Research & Development				
Signatures							
/s/Darren DeStefano, Attorney-in-Fact	01/2	26/2018					
**Signature of Reporting Person	1	Date					
Evaloretion of Doore		_					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.